Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 31
Back to Home
PT-141
Efficacy Rate80%
Studies3
Participants2,514
StatusAvailable

PT-141

Bremelanotide

PT-141 (Bremelanotide) is an FDA-approved melanocortin receptor agonist specifically designed to treat hypoactive sexual desire disorder in premenopausal women. Unlike other sexual health treatments, PT-141 works through the central nervous system to enhance sexual desire and arousal rather than affecting blood flow or hormones.

Clinical Benefits

FDA-approved for hypoactive sexual desire disorder (HSDD)
Increases sexual desire and motivation through brain pathways
Enhances sexual arousal and satisfaction
Reduces distress related to low sexual desire
Works through central nervous system, not vascular system
As-needed dosing - no daily medication required

Mechanism of Action

PT-141 functions as a selective melanocortin-4 receptor (MC4R) agonist in the central nervous system. Upon subcutaneous administration, bremelanotide crosses the blood-brain barrier and binds to MC4R receptors in the hypothalamus and other limbic structures involved in sexual behavior. This activation triggers downstream signaling cascades involving cyclic adenosine monophosphate (cAMP) and protein kinase A pathways, ultimately enhancing sexual motivation and desire through neuronal mechanisms rather than peripheral vascular effects.

Key Action:

Proven Results

%
Maximum Weight Loss
Clinical research data
0%
Diabetes Risk Reduction
Clinical research data
2,514
Total Participants
Research studies
0%
CV Risk Reduction
Clinical data

Medical Disclaimer

Clinical data presented is from peer-reviewed studies. Individual results may vary. Consult healthcare professionals before starting treatment. This information is for educational purposes only.